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Abstract
Long noncoding RNAs are capable of regulating gene expression at multiple levels. These RNA molecules are also involved in a
variety of physiological and pathological processes. Emerging data demonstrate that a series of differentially expressed long
noncoding RNAs are implicated in tumorigenesis. In the present study, we used microarray analysis to identify long noncoding
RNAs that are dysregulated in non-small-cell lung cancer when compared to normal lung tissues. Accordingly, we performed
quantitative real-time polymerase chain reaction to analyze the levels of long noncoding RNA and the cis target gene. We further
found the oncogene property of long noncoding RNA that long noncoding RNA downexpression inhibits non-small-cell lung
cancer cells proliferation and migration based on 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide and colony
formation assays and wound healing as well as transwell assays. The influence of long noncoding RNA on cell cycle of non-smallcell lung cancer cells is also analyzed by flow cytometry. Among the dysregulated long noncoding RNAs, we identified INS-IGF2
readthrough, transcript variant 1, noncoding RNA (NR_003512.3) is upregulated in non-small-cell lung cancer tissues, the cis gene
of which is insulin-like growth factor 2 gene hinted by bioinformatics analysis. We also observed that downregulation of INS-IGF2
readthrough, transcript variant 1, noncoding RNA reduces insulin-like growth factor 2 messenger RNA expression. Furthermore,
INS-IGF2 readthrough, transcript variant 1, noncoding RNA downregulation suppresses non-small-cell lung cancer cell proliferation and migration. This downregulation results in a concomitant inhibition of the G1/S transition in non-small-cell lung
cancer cells. Our findings suggest that INS-IGF2 readthrough, transcript variant 1, noncoding RNA may be an oncogene involved
in the development of lung cancer. Therefore, we speculate that INS-IGF2 readthrough, transcript variant 1, noncoding RNA
represents a potential therapeutic target for lung cancer.
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Introduction
Lung cancer, one of the most common malignancies worldwide, has become the leading cause of cancer-associated mortality, with approximately 1.8 million new cases reported
annually throughout the world.1 Among all cases with lung
cancer, non-small-cell lung cancer (NSCLC) constitutes
approximately 85%.2 Despite considerable advances in curative protocols, the prognosis for lung cancer remains unfavorable, with patient 5-year survival rates of approximately
15%.3 With this in mind, it is imperative that we elucidate
the mechanisms that underpin lung cancer development. It is
also important that we attempt to exploit new diagnostic biomarkers as well as therapeutic strategies for the treatment of
lung cancer.
Long noncoding RNAs (lncRNAs) are evolutionarily conserved transcripts consisting of more than 200 nucleotides
(per transcript). These RNA molecules do not have the capacity to encode for proteins. Accumulating evidence has demonstrated that lncRNAs are involved in a wide range of
biological functions, including cell-cycle progression, cell
growth, cell proliferation, and apoptosis.4 Therefore, dysregulation of lncRNAs plays a pivotal role in a variety of human
diseases, especially cancer, which are associated with the
development, invasion, and metastasis of tumors. 5 For
instance, the upregulation of the lncRNA HOTAIR contributes to the metastasis of breast cancer cells following the
transcriptional modulation of genes involved in cell development; 6 the metastasis-associated lung adenocarcinoma
transcript-1 (MALAT1) lncRNA is highly expressed in multiple types of cancers including lung adenocarcinoma and
hepatocellular carcinomas. The latter transcript is also
involved in the promotion of proliferation and metastasis of
cancer cells, suggesting concomitant involvement in oncogenic effects.7 Undoubtedly, aberrant lncRNA expression
also plays a regulatory role in lung cancer. It is widely
reported that 2420 lncRNAs are differentially expressed
between lung adenocarcinoma samples and normal lung tissue, suggesting that lncRNAs may be novel molecular biomarkers for diagnosing lung adenocarcinoma.8 At present,
several lung cancer-related lncRNAs including MALAT1,
ANRIL, H19, and HOTAIR,9 lncRNA GAS6-AS1 (GAS6
antisense RNA1),10 and lncRNA AK126698 have been identified.11 Further studies are required to identify additional
lncRNAs implicated in lung cancer and their associated
mechanisms of action.
In the present study, we analyzed the expression patterns of
lncRNAs in lung cancer tissues and the corresponding patterns

in adjacent nontumorous tissue by microarray analysis. Among
the differentially expressed lncRNAs, we found that INS-IGF2
readthrough (INS-IGF2), transcript variant 1, noncoding RNA
(lncINS-IGF2; NR_003512.3) was obviously elevated in lung
cancer tissues compared to normal tissues, and the role of
lncINS-IGF2 is unclear. Bioinformatics analysis further
showed that the cis gene of lncINS-IGF2 was insulin-like
growth factor 2 (IGF2) gene. The IGF2, a mitogenic peptide
hormone, plays a regulatory role in cell growth, differentiation,
and metabolism. Previous studies have shown that this hormone is abnormally expressed in various human malignancies,
and overexpressed IGF2 is closely associated with poor
prognosis in cancer.12-14 Collectively, we speculated that
lncINS-IGF2 might potentially be important in lung cancer
development. Next, we utilized small-interfering RNA
(siRNA)-mediated silencing in NSCLC cells to determine the
relationships between lncINS-IGF2 and IGF2 expression and
to investigate the impact of lncINS-IGF2 on cell proliferation
and metastasis of lung cancer cells. Our observations are likely
to provide a useful platform for future investigations into the
mechanisms that underpin lung cancer.

Materials and Methods
Patients and Specimens
The lung cancer samples and matched adjacent normal lung
tissue samples were gathered from the Affiliated Hospital of
Guangdong Medical University, China, between April 2012
and August 2013. None of the patients were subjected to preoperative chemotherapy and/or radiotherapy, and all patients
were diagnosed with NSCLC according to histopathology. Of
these samples, 3 were selected for lncRNA microarray analysis using an SBC-lncRNA (human 4  180 k) chip from
Shanghai Biotechnology Co, Ltd (Shanghai, China). All of
the extracted samples were immediately snap-frozen in liquid
nitrogen after resection. This work was approved by the
Ethics Committee of the Affiliated Hospital of Guangdong
Medical University, and all patients provided written
informed consent prior to study initiation.

Microarray Analysis
Three pairs of matched samples were used for microarray analysis. RNA was purified from total RNA after removal of ribosomal RNA (mRNA-ONLY eukaryotic messenger RNA
[mRNA] isolation kit, Epicentre, Madison, Wisconsin). Then,
each sample was transcribed into fluorescent complementary
RNA (cRNA) along the entire length of the transcripts without
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30 bias utilizing a random priming method. The labeled cRNAs
were hybridized onto the human lncRNA array v2.0 (8  60 k,
Arraystar).
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wavelength of 490 nm in a plate reader. All independent
experiments were performed 3 times.

Colony Formation Assay
Cell Culture and Transfection
The human lung cancer cell line (A549 and H1299) was
obtained from the Shanghai Cell Institute Country Cell Bank
(Shanghai, China). All cell lines were cultured in RPMI-1640
medium with 10% fetal bovine serum (Gibco/BRL, Maryland)
and grown at 37 C in a humidified atmosphere containing 5%
CO2. Cell transfection was performed with Lipofectamine
2000 reagent (Invitrogen, California) according to the manufacturer’s instructions. The siRNA against lncINS-IGF2 and
negative control siRNA were synthesized by Shanghai GenePharma Co Ltd (Shanghai, China). Oligonucleotides including
negative control siRNA and lncINS-IGF2 siRNA were synthesized by GenePharma.

RNA Extraction and Quantitative Real-Time Polymerase
Chain Reaction
Total RNA was extracted from cultured cell lines using Trizol
reagent (Invitrogen) according to the manufacturer’s protocol.
A total of 2 mg of total RNA were subsequently reverse transcribed using a PrimeScript real-time (RT) reagent kit with
genomic DNA Eraser (Takara, Otsu, Shiga, Japan); a final
volume of 20 mL was used to synthesize cDNA according to
the manufacturer’s protocol. Real-time quantitative polymerase chain reaction (qRT-PCR) was then conducted using the
SYBR Premix Ex Taq II PCR kit (Takara) following the
manufacturer’s instrument. The levels of lncINS-IGF2 transcript were measured using the following forward/reverse
primer pair: 50 -CCAGCAATCGGAAGTGAGC-3 0 and 50 GGACGTGGAACCGAGAGATT-30 . The levels of IGF2 transcript were measured using the following forward/reverse
primer pair: 5 0 -ATGCTGGTGCTTCTCACCTT-30 and 50 ACAGACGAACTGGAGGGTGT-30 . The human GAPDH
gene was utilized as an endogenous control and amplified with
the following forward/reverse primer pair: 5 0 -GACCTGACCTGCCGTCTA-3 0 and 50 -AGGAGTGGGTGTCGCT
GT-30 . Results were normalized to the content of GAPDH. All
experiments were performed in triplicate. The gene expression
fold-change values are represented using the 2DDCt method.

Cell Proliferation Assay
Cell proliferation was measured using 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assays
following the manufacturer’s instructions. In brief, 5000 cells
were plated into each well of a 96-well plate. The MTT reagent
was prepared at 5 mg/mL in phosphate-buffered saline (PBS).
The MTT stock solution (0.5 mg/mL) was then added to each
well. Cells were cultured for an additional 4 hours, and
dimethyl sulfoxide was subsequently added to dissolve the
resultant crystals before reading the absorbance at a

Five hundred cells were plated into each well in 6-well plates
in triplicate. After 14 days of incubation, cells were washed
with PBS, fixed with 4% paraformaldehyde, and subsequently
stained using 0.1% Crystal violet (Sigma, St Louis). Eventually, the number of effective colonies was counted. Colonies
consisting of more than 50 cells were defined as effective
colonies.

Cell Cycle Analysis
Cells were plated onto a 6-well plate at a density of 5  105
cells/well and grown for 24 hours. The cells were then starved
with serum-free culture medium for 24 hours to synchronize
them at the G1/S boundary, followed by transfection. After 48
hours, the cells were collected, washed twice with ice-cold
PBS, and fixed with 70% ice-cold ethanol at 4 C overnight.
After rehydration in PBS for 15 minutes, the cells were stained
for 30 minutes in the dark with propidium iodide solution and
then analyzed by flow cytometry (BD Biosciences, New York,
USA).

Wound-Healing Assays
Cells were seeded in 6-well plates at an initial density of 2 
105 cells/well and grown to about 80% to 90% confluence. A
vertical wound was created by scratching the monolayer with a
sterile 200-mL pipette tip, and the cells were then washed 3
times with PBS to remove the floating cells. The monolayer
was subsequently incubated in serum-free medium. At 0, 24,
48, or 72 hours following wound induction, photographs were
taken with a microscope at 200 magnification (Nikon, Japan)
at the same location in each well to monitor cell migration into
the wounded area.

Transwell Assay
Cell migration was evaluated using 8-mm pore size polycarbonate filter transwell inserts on the upper chamber with noncoated membranes (Corning, New York, USA). After siRNA
transfection for 24 hours, the cells were digested with trypsin
and then 5  104 transfected cells were diluted with serum-free
culture medium. The cells were plated into the upper chamber
(to which 200 mL of Dulbecco’s modified Eagle’s medium
without fetal bovine serum was added). The bottom chamber
was supplemented with 600 mL of 10% fetal bovine serum
medium. After incubating for 24 hours, the nonmigrated cells
in the upper chamber were removed with a cotton swab, and the
migrated cells in the lower chamber were fixed with 4% paraformaldehyde. All cells were stained using 0.1% Crystal violet (Sigma), and the cell numbers in each chamber were
counted in 5 random fields under the phase-contrast microscope. The migrated cells were visualized by photographing
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Figure 1. Relative expression levels of lncINS-IGF2 in lung cancer tissues and cell lines. A, lncINS-IGF2 expression was assessed following
microarray analysis of lung cancer tumor specimens (n ¼ 3) and normal adjacent lung tissue (n ¼ 3). B, The expression of lncINS-IGF2 was
measured by qRT-PCR in A549, H1299, and H441 lung cancer cell lines, HBE cells, 293T cells, and HeLa cells. *P < .05 versus normal group.
Results are expressed as the mean (SD) of the samples and each analysis was performed in triplicate. qRT-PCR indicates real-time quantitative
polymerase chain reaction; SD, standard deviation.

at 200 magnification using an Leica DMI3000B microscope.
Each experiment was repeated 3 times.

Statistical Analysis
Data were expressed as the mean (standard deviation). The
significance of intergroup differences was evaluated using 1way analysis of variance. Differences were considered significant at P < .05.

Results

A549 as well as H1299 cells. The lncINS-IGF2 siRNA was
transiently transfected into NSCLC cells to facilitate a reduction in the expression of lncINS-IGF2. The knockdown efficiency was verified by qRT-PCR assay, and the results
revealed that lncINS-IGF2 expression was significantly
reduced following transfection in A549 cells (Figure 2A) and
H1299 cells (Figure 2B). The levels of IGF2 mRNA in these 2
cell lines were further detected. Our results showed that downregulation of lncINS-IGF2 obviously reduced IGF2 mRNA
levels (Figure 2C and D) in NSCLC cells, indicating that
lncINS-IGF2 has positive regulation effect on IGF2 mRNA
expression levels in NSCLC cells.

lncINS-IGF2 is Upregulated in NSCLC Tissues
To explore the potential biological roles of lncRNAs in lung
cancer, we examined lncRNA expression profiles in human
lung cancer tissues using microarray analysis. We have primarily found the differential expression of several lncRNAs
including lncINS-IGF2 (data not published). As illustrated in
Figure 1A, the level of lncINS-IGF2 expression was approximately 4 times in lung cancer tissues more than nontumorous
tissue, suggesting that lncINS-IGF2 expression may correlate
with malignancy in lung cancer. Subsequently, we also measured the background expression of lncINS-IGF2 in HBE cells,
293T cells, HeLa cells as well as lung cancer cell lines including A549, H1299, and H441. We found that there existed background expression of lncINS-IGF2 in all 3 NSCLC cell lines:
HBE cells, 293T as well as HeLa cells (Figure 1B). In addition,
we selected A549 and H1299 cell lines for further study to
determine whether lncINS-IGF2 expression may correlate with
malignant behavior in lung cancer.

The Expression of IGF2 Was Reduced After lncINS-IGF2
Downregulation in NSCLC Cells
First, to clarify the relationship between the expression of IGF2
and lncINS-IGF2, RNA interference analysis was conducted in

Downregulation of lncINS-IGF2 Inhibits Cell Proliferation
and Colony Formation of NSCLC Cells
To further explore the role of lncINS-IGF2 in lung cancer, we
subsequently explored the impact of lncINS-IGF2 knockdown
on the proliferation of NSCLC cells. As illustrated in Figure
3A, proliferation of lncINS-IGF2 siRNA-transfected A549 and
H1299 cells were obviously repressed upon comparison with
the control groups (Figure 3A and B). Additionally, we also
studied the effect of lncINS-IGF2 downregulation on colony
formation in NSCLC cells. Our results demonstrated that the
number of colonies was decreased in siRNA lncINS-IGF2transfected A549 cells (Figure 3C) and was tendency to reduce
in lncINS-IGF2-downregulated H1299 cells (Figure 4D).
These data suggest that knockdown of lncINS-IGF2 inhibits
cell proliferation of NSCLC cells.

Downregulation of lncINS-IGF2 Inhibited G1/S Transition
of NSCLC Cells
To investigate the possible mechanisms underpinning lncINSIGF2-induced inhibition of cell proliferation in NSCLC cells,
we explored the effect of lncINS-IGF2 knockdown on the cell

Gao et al

5

Figure 2. lncINS-IGF2 knockdown results in downregulation of IGF2 in NSCLC cells. A549 and H1299 cells were transfected with control
siRNA or lncINS-IGF2 siRNA for 48 hours. The cells were subsequently harvested to assess knockdown effects (A and B). A549 and H1299
cells were transfected with NC and siRNA of lncINS-IGF2. IGF2 mRNA levels were measured by qRT-PCR assay (C and D). *P < .05 versus
NC. Data are expressed as the mean (SD) and each experiment was performed in triplicate. IGF2, insulin-like growth factor 2; NSCLC, nonsmall-cell lung cancer; siRNA, small interfering RNA; qRT-PCR, real-time quantitative polymerase chain reaction; NC, normal control; SD,
standard deviation.

cycle of lung cancer cells by flow cytometry. As shown in
Figure 4A, knockdown of lncINS-IGF2 resulted in an increase
in the proportion of A549 cells in the G1 phase with a concomitant reduction in the proportion of A549 cells in the S
phase. The similar results were observed in H1299 cells (Figure
4B). These observations suggested that lncINS-IGF2 knockdown may block G1/S transition.

lncINS-IGF2 siRNA Inhibits Cell Migration of NSCLC Cells
One of the features of metastasis, the main cause of death
among patients diagnosed with cancer, is the conversion to a
malignant cell phenotype.15 Thus, we also explored the effect
of lncINS-IGF2 depletion on metastasis of NSCLC cells using
wound-healing and transwell assays following transfection
with lncINS-IGF2-specific siRNA. We observed that lncINSIGF2 downregulation leads to an increase in the area of wound
healing (Figure 5A) and a decrease in the number of migratory
A549 cells (Figure 5C). The depressed migration ability was
also presented in lncINS-IGF2 siRNA-transfected H1299 cells
(Figure 5B and D). These data suggest that depletion of lncINSIGF2 inhibits the migration capacity of NSCLC cells.

Discussion
Lung cancer is the most common cause of cancer-associated
mortalities around the world, accounting for more than 25% of
the total number of cases with cancer.16 The development of
effective therapeutics for the treatment of lung cancer remains
a challenge due to properties including uncontrollable proliferation, metastasis, invasion, and defects the apoptotic pathways of cancer cells.17 It is well known that one of the main
reasons for poor therapeutic efficacy in lung cancer is latestage diagnosis. Therefore, the identification of higher specificity and sensitivity biomarkers would be extremely useful in
this regard.
The lncRNA molecules are usually more than 200 nt long
and frequently range up to 100 kb.18 It is well known that
lncRNAs are involved in a variety of cellular processes including proliferation,19 apoptosis,20 cell cycle,21 survival,22 and
migration.6 An ever-increasing number of studies have demonstrated that aberrant lncRNAs play crucial roles in many complicated human diseases including cancer.7-24 Furthermore,
dysregulated lncRNAs that have been observed in cancer
always function as oncogenes or tumor suppressor genes.25,26
However, the mechanism of action, biological activity, and
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Figure 3. lncINS-IGF2 knockdown inhibits cell proliferation and colony formation in NSCLC cells. A549 and H1299 cells transfected with
control siRNA or lncINS-IGF2 siRNA were trypsinized and plated into 96-well plates for the MTT assay. The asterisk shows the significant
differences on the proliferation rate between 2 groups (A and B). Colony formation of A549 and H1299 cells at 14 days after transfection with
the indicated oligonucleotides (C and D). *P < .05 versus NC. Data are expressed as the mean (SD) and each experiment was performed in
triplicate. NSCLC indicates non-small-cell lung cancer; siRNA, small interfering RNA; MTT, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-Htetrazolium bromide; NC, normal control; SD, standard deviation.

associated signaling pathways are yet to be elucidated for most
lncRNAs.
In the current study, we observed that lncINS-IGF2 was
upregulated in NSCLC tissues. In addition, our results demonstrate that downregulation of lncINS-IGF2 following siRNA
transfection decreases IGF2 mRNA levels and inhibits cell
proliferation as well as migration; this results in the concomitant inhibition of the G1/S transition. First, we analyzed the
expression profiles of lncRNA in lung cancer tissues in order to
characterize the potential biological function of lncRNAs in the
pathogenesis of lung cancer. The results of gene chip analyses
revealed a group of differentially expressed lncINS-IGF2. As
part of this analysis, results generated from gene chip analyses
revealed that lncINS-IGF2 is overexpressed in NSCLC tissues
compared to adjacent normal tissues. These observations

suggest that lncINS-IGF2 might play a role in tumorigenesis.
In order to better understand the biological role of lncINS-IGF2
in NSCLC cell lines, we used siRNA-mediated knockdown of
lncINS-IGF2 following transient transfection in A549 and
H1299 cells. Interestingly, bioinformatics analysis further
showed that the cis gene regulated by lncINS-IGF2 was IGF2
gene. Insulin-like growth factor 2 (IGF2) is a mitogenic peptide
hormone that is expressed in many tissues including lung tissue.27,28 The IGF2 plays a regulatory role in cell growth, differentiation, and metabolism. 29 Accumulating evidence
suggests that abnormalities in IGF2 expression occur during
cancer development and progression.30 In esophageal cancer,
increased IGF2 expression is closely associated with decreased
disease-free survival.31 Furthermore, it is reported that IGF2
downregulation decreases survival and adhesion of colorectal
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Figure 4. Downregulation of lncINS-IGF2 retards G1/S transition in NSCLC cells. A549 and H1299 cells were transfected with control siRNA
or lncINS-IGF2 siRNA for 48 hours. Cell populations at the G1, S, and G2/M phases were detected by flow cytometry. *P < .05 versus NC. Data
are expressed as the mean (SD) and the experiments were performed in triplicate. NSCLC indicates non-small-cell lung cancer; siRNA, small
interfering RNA; NC, normal control; SD, standard deviation.

cancer cells.32 Interestingly, IGF2 gene was identified as the
cis gene of lncINS-IGF2 revealed by the bioinformatics analysis. Therefore, we first explored the association between the
expression of IGF2 and lncINS-IGF2 by determining the
impact of lncINS-IGF2 silencing on IGF2 mRNA expression.
We observed that knockdown of lncINS-IGF2 resulted in a
concomitant reduction in the levels of IGF2 mRNA. These data
suggest that lncINS-IGF2 positively regulates IGF2 expression
in NSCLC cells, which might be associated with its modulation
on the flanking sequence such as the promoter of IGF2 gene
expression that affects gene expression. However, the precise
mechanism underpinning lncINS-IGF2-mediated modulation
of IGF2 remains unclear and requires further study.
To further investigate the function of lncINS-IGF2 on the
proliferation of NSCLC cells, an MTT assay and a colony
formation assay subsequently revealed that the downregulation
of lncINS-IGF2 markedly contributes to the inhibition of cell
proliferation in A549 cells. Dysregulation of the cell cycle is a
common occurrence during tumorigenesis. It is well known
that defective cell cycle progression plays a significant role
in cancer development.33,34 Therefore, we investigated whether
the impact of lncINS-IGF2 knockdown on NSCLC cells proliferation was mediated through regulation of the cell cycle.
Our results revealed that lncINS-IGF2 knockdown retarded cell
cycle as evidenced by an increased proportion of NSCLC cells

in the G1 phase. Conversely, we observed a reduction in the
proportion of NSCLC cells in the S phase after lncINS-IGF2
silencing. These data revealed that this reduction in lncINSIGF2 expression results in dysregulation of the cell cycle. Thus,
we speculate that the effect of lncINS-IGF2 knockdown on
NSCLC cells proliferation might be caused by lncINS-IGF2
knockdown-caused dysregulation of the cell cycle. Metastasis,
one of the properties that defines the malignant cell phenotype,
is the main cause of death in patients diagnosed with cancer.15
In this report, wound-healing and transwell assay analyses
revealed that the downregulation of lncINS-IGF2 obviously
inhibited the migration of NSCLC cells. Collectively, these
results indicate that lncINS-IGF2 promotes cell proliferation
and migration of NSCLC cells.
In conclusion, we observed upregulation of lncINS-IGF2
in NSCLC tissues and found that downregulation of lncINSIGF2 decreases IGF2 mRNA expression and inhibits cell proliferation and metastasis of NSCLC cells. According to these
findings, we propose that lncINS-IGF2 and IGF2 may represent important markers or targets in relation to NSCLC. However, more detail studies are required to further investigate the
mechanisms underlying lncINS-IGF2-modulated IGF2 gene
transcription as well as the potential importance of the interaction between these 2 factors in the development of lung
cancer.
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Figure 5. lncINS-IGF2 knockdown induces inhibition of cell migration in NSCLC cells. A, B, The migration capacity of A549 and H1299 cells
was determined using a wound-healing assay. Photographs were taken at 100 magnification at 0, 24, 48, and 72 hours after wounding; the
photographs were taken at the same location in each well. C, D, Representative images of the migration transwell assay; the number of migrated
cells was randomly measured by photograph at 200 magnification in 5 different fields for each chamber. *P < .05 versus NC. Data are defined
as mean (SD) following 3 independent experiments. NSCLC indicates non-small-cell lung cancer; NC, normal control; SD, standard deviation.
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